Clinical capability in the Gulf is real and it is recent. A7i tracks eleven programmes with published evidence of reaching a defined stage, spanning discovery, trials, approvals, local manufacturing and clinical adoption. Read as a set, they show a region that has become genuinely good at delivering advanced medicine, and that is now taking its first steps in originating it.
Where the capability is
King Faisal Specialist Hospital and Research Centre reported running 48% of clinical trials registered in Saudi Arabia in the first half of 2025. That is an extraordinary concentration for a national research base. It gives sponsors a single well-resourced counterparty, and it makes extending trial capacity to further sites the natural next step for the Kingdom.
In Abu Dhabi, the Emirati Genome Programme has been used to construct a trial cohort rather than describe a population. The Alzheimer's prevention trial run by IROS with the Department of Health and Halia Therapeutics identifies APOE4 carriers before symptoms appear. That is a genuinely distinctive use of a population dataset, and it is the first published instance of the Emirati data doing clinical work.
In Doha, Sidra Medicine administered a gene therapy for spinal muscular atrophy to Qatar's first patient, reported as the third country worldwide to do so. Delivering an advanced therapy requires a centre capable of handling it and a payer willing to fund it, and both are now demonstrably present.
Where origination begins
The Gulf-originated therapy among the eleven is the CAR-T therapy developed at King Faisal Specialist Hospital and Research Centre, approved by the SFDA for a Phase I trial in August 2025 and targeting relapsed CD19-positive acute lymphoblastic leukaemia using a closed transduction system. Discovery work on the region's own population data, including the Emirati Genome Programme population analysis, adds a second Gulf-originated strand.
Most of the others test, approve, deliver or manufacture assets invented elsewhere. The immunotherapy approved twice by the SFDA is American. The breast cancer therapy cleared early in the UAE is British-Swedish. The oral GLP-1 is American. The spinal muscular atrophy therapy is Swiss. The insulin being localised in Riyadh is Danish.
Early adoption of frontier medicine is a real achievement and it benefits patients immediately. It also places the region at the delivery end of the value chain today, with origination as the next stage.
The consanguinity argument, and how to capture it
High consanguinity rates in Gulf populations concentrate rare inherited disease, which makes the region unusually valuable for rare-disease and gene-therapy recruitment. This is repeated constantly, and it is true. The value of that recruitment advantage accrues to whoever owns the asset being tested. A population uniquely suited to trialling gene therapies captures the most value when it also owns the therapies being trialled.
Capturing it requires domestic assets to trial, which returns to the point in A7i's companies coverage: the preclinical layer is the next one to build. The CAR-T programme is the model, and the opportunity is to repeat it.